Cardiovascular
Ventricular Arrhythmia
15
Pipeline Programs↗
5
Active Trials↗
6
Companies Involved↗
Ventricular arrhythmia is an emerging landscape with 15 programs across 6 companies. The most active players are Sanofi, Gilead, RyCarma Therapeutics, Inc.. 4 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 24
Phase 33
Analysis
Trial Status
18
clinical trials
Completed8 · 44%
Unknown status3 · 17%
Terminated2 · 11%
Recruiting2 · 11%
Enrolling by invitation2 · 11%
Not yet recruiting1 · 6%
Clinical Trials
Trial Activity
18 trials
EDEN Intracardiac Electrogram Recording and Classifying System
Enrolling by invitation·National Heart, Lung, and Blood Institute (NHLBI)·Preclinical·NCT07137455·50 enrolled
VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms) Using Commercial Off-The-Shelf (COTS) Catheters, Early Feasibility Study
Enrolling by invitation·National Heart, Lung, and Blood Institute (NHLBI)·Preclinical·NCT06940752·30 enrolled
Atorvastatin For The Reduction Of Ventricular Arrhythmias
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00457340·220 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)